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Abstract The aim of this study was to evaluate the out-
comes using the dose-adjusted Berlin–Frankfurt–Munster
(BFM-90) regimen without radiotherapy in adolescents and
adults with T cell lymphoblastic lymphoma (T-LBL) at
Beijing Cancer Hospital. Between March 2004 and De-
cember 2013, 57 newly diagnosed T-LBL patients were
treated in our center. We retrospectively analyzed their
main clinical characteristics and prognosis. The media age
of the patients at diagnosis was 26 (range 14–54). At a
median follow-up of 24 months (range 5–119), 38 patients
(67 %) were alive. The estimated 3-year overall survival
(OS) rate and progression-free survival (PFS) rate were 64
and 60 %, respectively. Abnormal WBC at diagnosis, high
IPI and no early response were indicated as adverse
prognostic factors for both PFS and OS (p \ 0.05). There
was also a trend for better survival in autologous peripheral
blood stem cell transplantation (APBSCT) group as com-
pared to non-APBSCT group (3-year OS 83 vs. 57 %), but
without any significant difference. This study suggested
that the dose-adjusted BFM-90 protocol without irradiation
showed comparable long-term results in Chinese adoles-
cents and adults with T-LBL. APBSCT may become a
choice whether we can identify the best candidate.
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Introduction
T cell lymphoblastic lymphoma (T-LBL) and T cell acute
lymphoblastic leukemia (T-ALL) are categorized as precursor
T cell malignancy, frequently accompanied by a mediastinal
mass and a high prevalence of central nervous system (CNS)
involvement [1]. Because T-LBL cell marker expression
overlaps that of T-ALL, the clinical distinction between the
two entities is arbitrarily determined by the degree of bone
marrow (BM) involvement: Patients with more than 25 %
lymphoblasts are classified as having T-ALL, whereas those
with a lesser degree of marrow replacement are classified as
having T-LBL [2]. T cell lymphoblastic lymphoma/leukemia
accounts for approximately 3.4 % of all non-Hodgkin lym-
phomas (NHLs) in China [3]. The conventional CHOP-like
regimen produced low complete remission (CR) rate(17 %)
and short media overall survival (OS) (8.5 months) [4]. But
the prognosis of LBL has dramatically improved with the use
of intensive ALL-type chemotherapy regimens, with an
event-free survival (EFS) of 90 % in children and disease-free
survival (DFS) of 72 % in adults [5, 6]. Although the use of
ALL-type regimens such as BFM-90 regimen usually ac-
quired better survival rates, they brought more adverse events
as well as treatment-related death. The aim of this study was to
evaluate the outcomes using the dose-adjusted Berlin–
Frankfurt–Munster (BFM-90) regimen without radiotherapy
in adolescents and adults in our cancer center.
Materials and methods
Patients
Between March 2004 and December 2013, patients not
less than 14 years old with untreated T-LBL were
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retrospectively analyzed. All cases were pathologically diag-
nosed by biopsy material from a lymph node or tumor mass
according to WHO classification of hematological malig-
nancies in Beijing Cancer Hospital. A series of markers,
including CD1a, CD3, CD4, CD8, CD10, CD20, CD45RO,
CD79a, Ki-67 and terminal deoxynucleotidyl transferase
(TdT), were performed by immunohistochemistry.
A complete panel was performed at the time of baseline
staging, re-staging and final evaluation. This panel in-
cluded a full clinical history, physical examination, com-
plete hematological and biochemical tests, computed
tomography (CT) scans of neck, chest, abdomen and pel-
vic, or 18F-fluorodeoxyglucose positron emission tomog-
raphy (18 F-FDG-PET) if possible, cerebrospinal fluid
examination, BM aspirate and/or biopsy. Staging was
carried out according to the Ann Arbor system for NHL.
Diagnosis of central nervous system (CNS) disease was
made in case of blast cells found in the cerebrospinal fluid
(CSF) or cerebral infiltration on cranial CT. It is important
to note that patients who had more than 25 % blasts in the
BM but presented as a bulky tumor were also included in
this study.
Treatment
All patients received a dose-adjusted BFM-90 regimen
after they or their guardians signed the informed consent.
The protocol was derived from BFM-90 regimen using the
same major drugs (prednisone, vincristine, asparaginase,
cyclophosphamide, cytarabine, daunorubicin, doxorubicin,
methotrexate and 6-mercaptopurine), but the doses and
frequency of methotrexate and cytarabine were reduced.
Cranial prophylactic radiotherapy was omitted, but all pa-
tients received regular intrathecal chemotherapy. Local ir-
radiation was also omitted in this study. The protocols for
induction, consolidation, re-induction and maintenance are
listed in Table 1. If the patient achieved complete remis-
sion (CR) or partial remission (PR) and agreed to receive
high-dose chemotherapy plus autologous peripheral blood
stem cell transplantation (APBSCT), it should be given
after re-induction phase. After APBSCT, the patient would
continue with maintenance therapy.
Response evaluation and statistical analysis
Response was evaluated at the end of each phase of the
protocol according to Cheson criteria. Overall survival
(OS) was calculated from the date of diagnosis to the date
of death by any cause or the last follow-up in survivors.
Progression-free survival (PFS) was measured from the
date of diagnosis to the first sign of progression, relapse
after response, death from any cause or to the date of last
follow-up. Patients who were lost to follow-up were cen-
sored at the time of their last follow-up examination. OS
and PFS curves were estimated using the Kaplan–Meier
method and were compared using the log-rank test. Prog-
nostic factors affecting OS and PFS were assessed by the
log-rank test. Statistically significant differences were de-
fined as two-sided p values \ 0.05. All statistical analyses




A total of 57 patients were consecutive newly diagnosed as
T-LBL and treated with the dose-adjusted BFM-90 regi-
men in our study. Their characteristics are listed in Table 2.
Their age ranged from 14 to 54 years, with a median age of
26 years; 72 % cases were male. The majority of patients
presented with stage III or IV disease (47/57, 82 %). BM
infiltration was detected in 33 patients (58 %), 16 (28 %)
of whom had more than 25 % blast cells in the BM. Four
(7 %) cases were diagnosed as initial CNS invasion, in-
cluding two patients with concurrent CNS and BM in-
volvement. Twenty-two (39 %) patients presented with
bulky mass ([7.5 cm), and 23 (40 %) patients had LDH
levels higher than the institutional upper limit of normal
(ULN). White blood cells (WBC) were found to be ab-
normal in 24 (42 %) patients at diagnosis. Thirty-four
(60 %) patients were within international prognostic index
(IPI) group 0–1, while 23 were within IPI group 2–4.
Thirty-four (69 %) patients had a Ki-67 score C75 % (data
unavailable in eight patients).
Therapeutic results and survival
Forty-three (75 %) patients achieved CR and 11 (19 %)
achieved PR after induction phase. Among those who
achieved CR, 16 patients proceeded to APBSCT. One pa-
tient who only achieved PR also received APBSCT after
re-induction phase. Three patients had progression disease
after induction treatment. Two of them died at 6 and
8 months, respectively. The other patient received a sal-
vage therapy and was still alive at his last follow-up visit.
At a median follow-up of 24 months (range 5–119) for
all patients, 38 patients (67 %) were alive. The estimated
3-year OS and PFS were 64 % and 60 %, respectively
(Figs. 1, 2). The 3-year OS and PFS were significantly
better in patients with normal WBC counts at diagnosis as
compared to those with abnormal WBC counts (79 vs.
44 %, p = 0.033; 76 vs. 31 %, p = 0.031, respectively)
(Figs. 3, 4). The 3-year OS and PFS probability was
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significantly worse in IPI group 2–4 when compared to IPI
group 0–1 (45 vs. 74 %, p = 0.027; 34 vs. 80 %,
p = 0.004, respectively) (Figs. 5, 6). Patients with elevated
LDH at diagnosis were significantly associated with poor
3-year PFS (40 %, p = 0.023), but there was no statisti-
cally difference in the 3-year OS (p = 0.154). There was a
significant difference between 3-year OS and PFS by
treatment response. A trend of better survival was shown in
APBSCT group as compared to non-APBSCT group (3-
year OS: 83 vs. 57 %; 3-year PFS: 75 vs. 54 %); however,
the result did not show significant difference. There was no
statistically difference in 3-year OS or PFS according to
gender, stage, Ki-67, CNS involvement, BM involvement
or bulky mass (Table 2).
Twenty-five patients experienced progression or relapse.
Among them, 23 cases progressed or relapsed during the
first 2 years and the other two cases relapsed at 36 and
68 months, respectively. Sites of relapse included lymph
node (n = 17), BM (n = 6) and CNS (n = 2). All patients
with BM relapse had BM involvement at diagnosis, but
only one patient with CNS relapse had CNS invasion at
diagnosis. All of the patients with BM or CNS relapse died.
Seven patients with lymph node relapse were alive at the
last visit. Five cases were still in salvage therapy, but only
one of them achieved PR. One patient accepted allogeneic
stem cell transplant and remained in CR at 52 months of
follow-up. One patient only accepted salvage chemother-
apy and showed no sign of progression at 96 months.
Table 1 Protocols of modified BFM-90
Drugs Doses Days
Induction phase 1a
Prednisone (PDN) 60 mg/m2 oral 1–28, then taper over 3 9 3 days
Vincristine (VCR) 1.5 mg/m2 (max 2 mg) IV 8,15,22,29
Daunorubicin (DNR) 30 mg/m2 IV 8,15,22,29
L-asparaginase (L-ASP) Or Pegasparaginase 6,000 IU/m2 IV Or 2500 IU/m2 IM 8–15 Or 8,22
aIT chemotherapy b1,15
Induction phase 1b
Cyclophosphamide (CTX) 1000 mg/m2 IV 1,15
Cytarabine (Ara-C) 75 mg/m2 IV 3–6, 17–20
6-Mercaptopurine (6-MP) 60 mg/m2 oral 1–28
aIT chemotherapy 1,15
Consolidation phase
6-Mercaptopurine (6-MP) 25 mg/m2 oral 1–28
c Methotrexate (MTX) 3000 mg/m2 IV 1,15
aIT chemotherapy 1,15
Reinduction phase 2a
Dexamethasone (DXM) 9 mg/m2 oral 1–21, then taper over 3 9 3 days
Vincristine (VCR) 1.5 mg/m2 (max 2 mg) IV 1,8,15,22
Daunorubicin (DNR) 30 mg/m2 IV 1,8,15,22
L-asparaginase (L-ASP) Or Pegaspargase 6,000 IU/m2 IV Or 2500 IU/m2 IM 1–8 Or 1,15
aIT chemotherapy 1,15
Reinduction phase 2b
Cyclophosphamide (CTX) 1000 mg/m2 IV 1,15
Cytarabine (Ara-C) 75 mg/m2 IV 3–6, 17–20
6-Mercaptopurine (6-MP) 60 mg/m2 oral 1–28
aIT chemotherapy 1,15
Maintenance phase
Methotrexate (MTX) 20 mg/m2 oral Once a week for 12 months
6-Mercaptopurine (6-MP) 60 mg/m2 oral Daily for 12 months
a Intrathecal (IT) chemotherapy with cytarabine (50 mg) and/or methotrexate (10 mg) and dexamethasone (5 mg)
b If the patient had CNS involvement at diagnosis, two doses IT would be added at day 8 and 22
c One-tenth of the methotrexate dose was administered within 0.5 h, and nine-tenths given by intravenous (IV) drip over 23.5 h, Citrovorum
folinate rescue was given at a dose of 30 mg/m2 at 36 h and then 15 mg/m2 at 42, 48, 54, 60, 66, 72, 78 and 84 h
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Toxicity
No death occurred due to toxicity. The most common
grade 3 and 4 adverse events were hematologic events,
including neutropenia (in 86 % cases), thrombocytopenia
(in 56 %), anemia (in 49 %) and febrile neutropenia (in
46 %). Grade 3 aminotransferase elevation was seen in
six patients. One patient developed acute renal failure
due to high-dose methotrexate, and one patient suffered
from acute pancreatitis due to pegylated asparaginase.
No other grade 3 or 4 non-hematologic adverse events
occurred.
Discussion
T cell lymphoblastic lymphoma (T-LBL) is an uncommon,
aggressive but curable T cell lymphoma in adult, but more
common in younger adults [7]. In our study, the patients
showed clinical characteristics as published data: younger
age, predominantly male, advanced stage and higher BM
involvement.
In our study, we tried the dose-adjusted BFM-90 regi-
men and observed a CR rate of 75 % and a PR rate of 19 %
at the end of induction phase, and the 3-year PFS and OS
were 60 and 64 %, respectively. Despite the lower CR rate,
Table 2 Patients’
characteristics and prognostic
factors for overall survival (OS)
and progression-free survival
(PFS)
Variable Number (%) 3-year OS (%) p value 3-year PFS (%) p value
Gender
Male 41 (72 %) 63 58
Female 16 (28 %) 69 0.965 70 0.879
Stage
I ? II 10 (18 %) 80 88
III ? IV 47 (82 %) 60 0.138 53 0.085
Ki-67
C75 % 34 (69 %) 71 67
\75 % 15 (31 %) 60 0.283 52 0.518
LDH
[ULN 23 (40 %) 47 40
BULN 34 (60 %) 76 0.154 72 0.023
WBC
Normal 33 (58 %) 79 76
Abnormal 24 (42 %) 44 0.033 37 0.031
CNS involvement
Yes 4 (7 %) 50 25
No 53 (93 %) 67 0.351 65 0.180
BM involvement
Yes 33 (58 %) 57 42
No 24 (42 %) 72 0.130 76 0.060
Bulky mass([ 7.5 cm)
Yes 22 (39 %) 65 67
No 35 (61 %) 64 0.731 56 0.645
IPI
0–1 34 (60 %) 80 80
2–4 23 (40 %) 45 0.027 34 0.004
Response
CR 43 (75 %) 74 69
PR 11 (19 %) 41 23
PD 3 (5 %) 0 0.000 0 0.000
APBSCT
Yes 17 (30 %) 83 75
No 40 (70 %) 57 0.133 54 0.064
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we achieved a comparable overall response rate (ORR
94 %) and long-term outcome, comparing favorably with
those obtained in Thomas et al. study and Wang K et al.
study [8, 9]. The most common grade 3 and 4 adverse
events still were hematologic events, but overall tolerance
was acceptable with no treatment-related mortality. It
showed that our dose-adjusted BFM-90 regimen had
similar efficacy and acceptable toxicity.
Relapse and progression occurred in 25 of 57 patients in
this study, and their outcomes were very poor. If we ex-
cluded the five alive patients on therapy, only two patients
survived free of the disease in this study, supporting lit-
erature about the difficulty in salvaging patients with re-
current T-LBL [10–12]. More effective new drugs such as
nelarabine and NOTCH-1 inhibitors are needed to improve
the outcome of patients with relapsed disease. Most
relapses occurred within the first 2 years, similar to Ter-
muhlen et al. report [13]. But it should be noted that late
relapse still happened up to 68 months. Lymph nodes (17/
25) remained the most common site of relapse, but with
disseminated sites, which suggested that local irradiation
might not prevent relapse and systemic therapy was more
important. There are no sufficient data to analyze the
specific precise values of intrathecal therapy, systemic




































































































Fig. 4 Progression-free survival stratified by white blood cell counts
at diagnosis
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prophylaxis methods. Consecutive studies from the BFM
group introduced four doses of intravenous methotrexate at
5 g/m2, and in NHL/BFM-95, prophylactic cranial irra-
diation was safely eliminated [5, 14]. The Children’s
Cancer Group (CCG) improved the outcome in ALL pa-
tients using a modified BFM approach without high-dose
methotrexate or cranial irradiation, and CNS prophylaxis
was frequent delivery of intrathecal chemotherapy [13, 15].
In our study, we gave patients two doses of intravenous
methotrexate at 3 g/m2 combined with 10–12 doses
intrathecal chemotherapy without prophylactic cranial
irradiation. Two patients (3.5 %, 2/57) had CNS relapse,
and one of them had CNS invasion at diagnosis. The in-
cidence of CNS relapse occurred in our group was com-
parable to that reported by Hoelzer et al. [6] and Mo¨ricke
et al. [16], all less than 5 %. The low incidence of CNS
relapse supports the efficacy of such CNS prophylaxis
method, but it needs larger scale and prospective trials to
confirm.
Song et al. [17] suggested consolidation with SCT in
first response in chemosensitive T-LBL adult patients,
which showed favorable long-term outcome [17]. Sweet-
enham et al. [18] conducted a prospective multicenter
randomized trial to determine whether autologous stem cell
transplantation (ASCT) was superior to conventional-dose
consolidation and maintenance chemotherapy (CC) as
post-remission therapy in LBL. With a median follow-up
of 37 months, the actuarial 3-year relapse-free survival rate
was 24 % for the CC arm and 55 % for the ASCT arm
(p = 0.065). The OS rates were 45 and 56 %, respectively
(p = 0.71). In our study, 17 patients proceeded with
APBSCT followed by maintenance therapy. There was also
a trend for better survival in APBSCT group compared to
non-APBSCT group (3-year OS: 83 vs. 57 %); however,
the result did not show significance difference. We need to
increase the number of patients and identify the best can-
didate for APBSCT.
To date, reliable and reproducible prognostic factors for
adult LBL have not been described [6, 9, 13, 19]. This study
confirms the previously published findings that gender,
stage, a bulky mass, elevated LDH, CNS or BM infiltration
did not have a significant effect on OS. And in our series,
abnormal WBC at diagnosis and high IPI were indicated as
adverse prognostic factors for both EFS and OS, in contrast
to report from Hoelzer et al. [6]. We also found that early
response in such patient was an important prognostic factor.
Patients who achieved CR or PR after induction therapy
(8 weeks) acquired a better outcome. This suggests that we
should adjust the treatment strategy as earlier as response
evaluation is not satisfactory after induction regimen.
This study suggested that the dose-adjusted BFM-90
protocol without irradiation showed comparable long-term
survival and control of CNS recurrence in Chinese ado-
lescents and adults with T-LBL. Although APBSCT in this
group did not improve survival, it may become a choice
whether we can identify the best candidate.
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Fig. 6 Progression-free survival stratified by IPI score at diagnosis
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